31.07.2013 • News

Dow Chemical EBITDA up 9% in Q2

U.S. chemical giant Dow Chemical saw adjusted EBITDA gain nearly 9% year-on-year to $ 2.1 billion in Q2 2013, thanks mainly to strong business in the Agricultural Science and Performance Plastics segments. The unusually large adjustment reflects a payment of $2.2 from Petrochemical Industries Company of Kuwait in arbitration over the K-Dow joint venture canceled by Kuwait in 2009. Quarterly sales were flat at $14.6 billion. Led by activities in emerging markets that more than offset a decline in Europe, volume growth averaged 9%, said CEO Andrew Liveris. Prices receded by 2%, due in part to currency translations. 

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read